SeaBeLife Biotech
Created in 2019
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
1,733Activities
Technologies
Entity types
Location
Pl. Georges Teissier, 29680 Roscoff, France
Roscoff
France
Employees
Scale: 2-10
Estimated: 15
Engaged corporates
15
4 12Added in Motherbase
1 year, 10 months ago
biotech Value proposition
Solutions to deprogram cell death : A breakthrough innovation to treat and prevent severe pathologies
We develop small molecules that inhibit regulated necrosis using an original mechanism of action. Regulated necrosis is one of the recently identified pathophysiological factors in many diseases with severe outcomes. The technical, therapeutic and economic potential is major. Our activity focuses on the development of drugs inhibiting regulated necrosis, from the selection of the molecule to the proof of efficacy in the patient. We focus on acute and orphan diseases because preclinical and clinical development is facilitated, allowing proof of concept (POC) to be provided in humans more quickly. We have selected a lead molecule which is currently under preclinical development to treat acute kidney injury (AKI) induced by anti-cancer treatments (such as cisplatin) and to treat acute liver failure (ALF) induced by paracetamol poisoning. We have already identified molecules in our pipeline for which we obtained in cellulo POC in Neurodegenerative diseases and AMD.
Nécrose régulée, Insuffisance rénale aiguë, Insuffisance hépatique aiguë, Ferroptose, Nécroptose, Intoxication médicamenteuse, néphrotoxicité, hépatotoxicité, maladies neurodégénératives, Paracetamol, and CisplatineOriginal language
Une innovation de rupture pour combattre la mort cellulaire
SeaBeLife développe des molécules innovantes pour traiter des pathologies sévères impliquant la nécrose régulée. Nos molécules brevetées s'attaquent à la mort cellulaire selon un mécanisme d'action original. Le potentiel thérapeutique et économique est majeur, la nécrose régulée joue un rôle clé dans la pathogenèse de maladies graves: insuffisances hépatique ou rénale aiguë, ischémies cardiaque et cérébrale, maladies neurodégénératives et DMLA.
Seabelife – Sea inspired and life oriented biotech
https://www.seabelife.com/fr/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 EY Consulting, audit, IT Services and IT Consulting | EY Consulting, audit, IT Services and IT Consulting | Other 4 Jun 2024 | | |
 Viva Technology Trade show, IT Services and IT Consulting | Viva Technology Trade show, IT Services and IT Consulting | Other 5 Apr 2024 | | |
 Groupe Crédit Agricole Bank, Banking | Groupe Crédit Agricole Bank, Banking | Other 24 Mar 2024 | | |
 La French Tech Brest Bretagne Ouest French Tech, Government Relations Services | La French Tech Brest Bretagne Ouest French Tech, Government Relations Services | Other 2 Dec 2023 | | |
 WeLike Startup accelerator & VC, Venture Capital and Private Equity Principals | WeLike Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 26 Sep 2023 | | |
 CNRS Innovation Research, Research Services | CNRS Innovation Research, Research Services | Other 19 Jan 2024 | | |
 European Commission European Union, Environmental Services | European Commission European Union, Environmental Services | Other 5 May 2023 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 18 Mar 2024 | | |
 Technopôle Brest-Iroise Business Consulting and Services | Technopôle Brest-Iroise Business Consulting and Services | Other 17 Dec 2023 | | |
 CNRS Research, Research Services | CNRS Research, Research Services | Other 15 Dec 2023 | | |